Business Context and Reporting Period
This Form 8-K Current Report was filed by Leap Therapeutics, Inc. on June 21, 2017. The registrant is an emerging growth company incorporated in Delaware, headquartered in Cambridge, MA. The report details a strategic partnership entered into on the date of the filing.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material definitive agreement and does not contain financial statements or performance data.
Material Changes and Agreements
On June 21, 2017, Leap Therapeutics entered into a Clinical Trial Collaboration and Supply Agreement with MSD International GmbH, a subsidiary of Merck (known as MSD outside the U.S. and Canada). Key terms include:
- Objective: To clinically evaluate the combination of Leap's DKK1 antagonist (DKN-01) with Merck's PD-1 antagonist, KEYTRUDA (pembrolizumab).
- Scope: Phase I/II clinical trials assessing safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with relapsed or refractory advanced esophagogastric cancers.
- Responsibilities: Leap will sponsor and fund the trials. Merck will manufacture and supply KEYTRUDA.
- Data Ownership: Clinical data generated from the trial will be jointly owned by Leap and Merck.
- Term: The agreement expires upon delivery of the final study report, subject to earlier termination for material breach, safety concerns, regulatory actions, or discontinuation of compound development.
Outlook, Risks, and Management Commentary
Management highlighted the strategic value of combining DKN-01 with KEYTRUDA to target advanced esophagogastric cancers. The filing notes standard termination contingencies, including uncured material breach, safety concerns, regulatory actions preventing supply, or withdrawal of regulatory approval for either compound. No specific financial guidance or forward-looking revenue projections were included in this document.
Investor Verification Checklist
- Verify the specific clinical trial design and patient enrollment criteria for the Phase I/II study.
- Confirm the funding obligations and budget allocated by Leap for the trial.
- Review the joint data ownership terms to understand future commercialization rights.
- Monitor regulatory filings for the initiation of the clinical trial.
- Check for any subsequent updates regarding the safety or efficacy of the DKN-01 and KEYTRUDA combination.